Manal Saleh

For high-res images, please click here

Abu Dhabi, UAE — February 2026 CellSave Arabia, the region’s first and largest private stem cell laboratory and a pioneer in regenerative medicine and part of CSG.BIO, is proud to announce that it has been qualified by Gilead and Kite to provide cell storage services to cell therapy treatment centers in UAE. Through this collaboration, CellSave Arabia will serve as a qualified provider of cell storage services for cells used in Gilead and Kite’s treatment pathways for lymphoma patients.

This marks an important milestone in strengthening access to advanced cancer therapies. By combining CellSave Arabia’s state-of-the-art biobanking capabilities with Gilead and Kite’s proven leadership in CAR T-cell therapy, the collaboration aims to support a smoother, faster, and more efficient patient pathway for those requiring advanced cellular treatments for lymphoma.

Kite, a Gilead company, is the global leader in cell therapy, with a goal to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Following its acquisition by Gilead Sciences in 2017, Kite accelerated the development of breakthrough CAR T-cell therapies, including YESCARTA® and TECARTUS®, which have transformed treatment outcomes for certain lymphomas. Today, more than 32,000 patients have been treated with Kite’s CAR T-cell therapies at more than 555 authorised treatment centres globally. Currently, Kite has two approved CAR T-cell therapies across four indications in the UAE. Kite is the only company dedicated exclusively to the research, development, manufacturing, and commercialization of cell therapy on a global scale.

CellSave Arabia will support the delivery of Gilead and Kite cell therapy products by providing secure and accredited handling and storage of cellular material - an essential step in the delivery of CAR T-cell therapy. With internationally recognised accreditations including AABB, FDA and ISO 2038, CellSave Arabia operates with the highest global standards for cell preservation, making it uniquely positioned to support advanced oncology treatments in partnership with leading biopharmaceutical innovators.

Alia Abdel-Razeq, COO of CellSave Arabia, stated:

“Our mission has always been to place patients at the center of every innovation we pursue. Working alongside Gilead and Kite allows us to support lymphoma patients with the highest level of precision, safety, and care—ensuring their cells are preserved in the highest standards.”

Eslam Khedr, Head of Oncology Regional Headquarters, Gilead and Kite Middle East added:

“CAR-T therapy is a truly individualised treatment with an intent to cure patients with difficult-to treat-blood cancers. At the heart of meeting the needs of these patients, their families, caregivers and their HCPs is ensuring the highest quality in the treatment delivery infrastructure. Kite has taken a unique approach to scaling the technology of cell therapy, combining capacity, speed, and reliability with the largest in-house cell therapy manufacturing network in the world to rapidly deliver products to our authorised treatment centers.”

This collaboration reflects both organizations’ commitment to improving the treatment landscape for patients with lymphoma in the region. It also reinforces the UAE’s growing position as a regional hub for next-generation therapeutics, biomedical innovation, and high-impact scientific partnerships.

Together, CellSave Arabia and Gilead and Kite aim to contribute to faster, more efficient access to cutting-edge cellular therapies, ultimately improving patient outcomes and expanding hope for individuals affected by difficult-to-treat blood cancers.

-END-